• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Priming of the Respiratory Tract with Immunobiotic Lactobacillus plantarum Limits Infection of Alveolar Macrophages with Recombinant Pneumonia Virus of Mice (rK2-PVM).用免疫益生菌植物乳杆菌对呼吸道进行预处理可限制肺泡巨噬细胞被重组小鼠肺炎病毒(rK2-PVM)感染。
J Virol. 2015 Nov 4;90(2):979-91. doi: 10.1128/JVI.02279-15. Print 2016 Jan 15.
2
Critical Adverse Impact of IL-6 in Acute Pneumovirus Infection.白细胞介素-6 在急性呼吸道合胞病毒感染中的关键不良影响。
J Immunol. 2019 Feb 1;202(3):871-882. doi: 10.4049/jimmunol.1800927. Epub 2018 Dec 21.
3
Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.暴露后给予免疫益生菌乳酸杆菌可避免呼吸道病毒感染的致命后遗症。
Antiviral Res. 2015 Sep;121:109-19. doi: 10.1016/j.antiviral.2015.07.001. Epub 2015 Jul 2.
4
Lactobacillus priming of the respiratory tract: Heterologous immunity and protection against lethal pneumovirus infection.呼吸道乳杆菌的预刺激:异源免疫和对致死性呼吸道合胞病毒感染的保护。
Antiviral Res. 2013 Mar;97(3):270-9. doi: 10.1016/j.antiviral.2012.12.022. Epub 2012 Dec 26.
5
Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection.乳酸菌介导的呼吸道黏膜预适应可预防致死性呼吸道合胞病毒感染。
J Immunol. 2011 Jan 15;186(2):1151-61. doi: 10.4049/jimmunol.1001751. Epub 2010 Dec 17.
6
The Role of Alveolar Macrophages in the Improved Protection against Respiratory Syncytial Virus and Pneumococcal Superinfection Induced by the Peptidoglycan of CRL1505.CRL1505 肽聚糖诱导的肺泡巨噬细胞在改善呼吸道合胞病毒和肺炎链球菌再感染中的作用
Cells. 2020 Jul 9;9(7):1653. doi: 10.3390/cells9071653.
7
Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infection.通过模式识别受体NOD2和TLR2发出的信号有助于对致死性肺病毒感染进行免疫调节控制。
Antiviral Res. 2016 Aug;132:131-40. doi: 10.1016/j.antiviral.2016.06.002. Epub 2016 Jun 14.
8
Depletion of alveolar macrophages prolongs survival in response to acute pneumovirus infection.肺泡巨噬细胞耗竭可延长急性呼吸道合胞病毒感染后的存活时间。
Virology. 2012 Jan 20;422(2):338-45. doi: 10.1016/j.virol.2011.10.031. Epub 2011 Nov 30.
9
Rhinovirus Reduces the Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and -Independent Mechanisms.鼻病毒通过干扰素依赖和非依赖机制降低随后的呼吸道病毒感染的严重程度。
mSphere. 2021 Jun 30;6(3):e0047921. doi: 10.1128/mSphere.00479-21. Epub 2021 Jun 23.
10
Innate immune protection from pneumonia virus of mice induced by a novel immunomodulator is prolonged by dual treatment and mediated by macrophages.新型免疫调节剂诱导的小鼠肺炎病毒先天免疫保护作用通过双重治疗延长,并由巨噬细胞介导。
Antiviral Res. 2019 Nov;171:104594. doi: 10.1016/j.antiviral.2019.104594. Epub 2019 Aug 27.

引用本文的文献

1
Towards airway microbiome engineering for improving respiratory health.致力于气道微生物组工程以改善呼吸健康。
Adv Drug Deliv Rev. 2025 Aug 6;225:115662. doi: 10.1016/j.addr.2025.115662.
2
Short-Chain Fatty Acids: Promising Therapeutic Targets for Respiratory Syncytial Virus Infection.短链脂肪酸:呼吸道合胞病毒感染的潜在治疗靶点
Clin Rev Allergy Immunol. 2025 Jan 28;68(1):8. doi: 10.1007/s12016-024-09018-x.
3
Synergy between and anti-PcrV antibody delivered in the airways to boost protection against .气道内递送的[具体物质]与抗PcrV抗体之间的协同作用,以增强对[具体病原体]的保护。 (注:原文中部分内容缺失,以上是根据格式要求进行的补充翻译)
Mol Ther Methods Clin Dev. 2024 Aug 30;32(4):101330. doi: 10.1016/j.omtm.2024.101330. eCollection 2024 Dec 12.
4
The Mucus-Binding Factor Mediates CRL1505 Adhesion but Not Immunomodulation in the Respiratory Tract.黏液结合因子介导CRL1505在呼吸道的黏附,但不介导免疫调节。
Microorganisms. 2024 Jun 16;12(6):1209. doi: 10.3390/microorganisms12061209.
5
Emerging Multiscale Biofabrication Approaches for Bacteriotherapy.用于细菌疗法的新兴多尺度生物制造方法
Molecules. 2024 Jan 22;29(2):533. doi: 10.3390/molecules29020533.
6
Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies.抗病毒和抗炎的植物源生物活性化合物及其在治疗COVID-19相关病症中的潜在用途。
J Xenobiot. 2022 Oct 8;12(4):289-306. doi: 10.3390/jox12040020.
7
The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19.呼吸道微生物群在预防病毒性疾病中的作用:呼吸道共生细菌作为COVID-19的下一代益生菌
Biosci Microbiota Food Health. 2022;41(3):94-102. doi: 10.12938/bmfh.2022-009. Epub 2022 Mar 29.
8
Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?囊性纤维化的肺部定向细菌疗法:它会是一种选择吗?
Antibiotics (Basel). 2022 Feb 28;11(3):326. doi: 10.3390/antibiotics11030326.
9
Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice.鼻内接种乳杆菌可预防小鼠铜绿假单胞菌性急性肺炎。
BMC Microbiol. 2021 Jun 28;21(1):195. doi: 10.1186/s12866-021-02254-7.
10
Rhinovirus Reduces the Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and -Independent Mechanisms.鼻病毒通过干扰素依赖和非依赖机制降低随后的呼吸道病毒感染的严重程度。
mSphere. 2021 Jun 30;6(3):e0047921. doi: 10.1128/mSphere.00479-21. Epub 2021 Jun 23.

本文引用的文献

1
The heterogeneity of lung macrophages in the susceptibility to disease.肺巨噬细胞在疾病易感性方面的异质性。
Eur Respir Rev. 2015 Sep;24(137):505-9. doi: 10.1183/16000617.0031-2015.
2
Immunobiotic Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection.暴露后给予免疫益生菌乳酸杆菌可避免呼吸道病毒感染的致命后遗症。
Antiviral Res. 2015 Sep;121:109-19. doi: 10.1016/j.antiviral.2015.07.001. Epub 2015 Jul 2.
3
Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes.肺泡巨噬细胞衍生的I型干扰素通过募集抗病毒单核细胞来协调对呼吸道合胞病毒的先天免疫。
J Exp Med. 2015 May 4;212(5):699-714. doi: 10.1084/jem.20140825. Epub 2015 Apr 20.
4
Alveolar macrophages and type I IFN in airway homeostasis and immunity.肺泡巨噬细胞和 I 型干扰素在气道稳态和免疫中的作用。
Trends Immunol. 2015 May;36(5):307-14. doi: 10.1016/j.it.2015.03.005. Epub 2015 Apr 3.
5
High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.用于鉴定呼吸道合胞病毒(RSV)抑制剂的高通量命中筛选级联
J Biomol Screen. 2015 Jun;20(5):597-605. doi: 10.1177/1087057115569428. Epub 2015 Feb 5.
6
The development and function of lung-resident macrophages and dendritic cells.肺驻留巨噬细胞和树突状细胞的发育和功能。
Nat Immunol. 2015 Jan;16(1):36-44. doi: 10.1038/ni.3052.
7
Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review.益生菌预防小儿上呼吸道感染:一项系统评价
Expert Opin Biol Ther. 2015 Jan;15(1):9-20. doi: 10.1517/14712598.2015.980233. Epub 2014 Nov 28.
8
Oral GS-5806 activity in a respiratory syncytial virus challenge study.呼吸道合胞病毒挑战研究中口服 GS-5806 的活性。
N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.
9
Pneumolysin expression by streptococcus pneumoniae protects colonized mice from influenza virus-induced disease.肺炎链球菌表达的肺炎溶血素可保护定殖小鼠免受流感病毒诱导的疾病侵害。
Virology. 2014 Aug;462-463:254-65. doi: 10.1016/j.virol.2014.06.019. Epub 2014 Jul 5.
10
Eosinophils and respiratory virus infection: a dual-standard curve qRT-PCR-based method for determining virus recovery from mouse lung tissue.嗜酸性粒细胞与呼吸道病毒感染:一种基于双标准曲线qRT-PCR的方法用于测定小鼠肺组织中的病毒回收率。
Methods Mol Biol. 2014;1178:257-66. doi: 10.1007/978-1-4939-1016-8_22.

用免疫益生菌植物乳杆菌对呼吸道进行预处理可限制肺泡巨噬细胞被重组小鼠肺炎病毒(rK2-PVM)感染。

Priming of the Respiratory Tract with Immunobiotic Lactobacillus plantarum Limits Infection of Alveolar Macrophages with Recombinant Pneumonia Virus of Mice (rK2-PVM).

作者信息

Dyer Kimberly D, Drummond Rebecca A, Rice Tyler A, Percopo Caroline M, Brenner Todd A, Barisas Derek A G, Karpe Kendal A, Moore Martin L, Rosenberg Helene F

机构信息

Inflammation Immunobiology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

J Virol. 2015 Nov 4;90(2):979-91. doi: 10.1128/JVI.02279-15. Print 2016 Jan 15.

DOI:10.1128/JVI.02279-15
PMID:26537680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4702661/
Abstract

UNLABELLED

Pneumonia virus of mice (PVM) is a natural rodent pathogen that replicates in bronchial epithelial cells and reproduces many clinical and pathological features of the more severe forms of disease associated with human respiratory syncytial virus. In order to track virus-target cell interactions during acute infection in vivo, we developed rK2-PVM, bacterial artificial chromosome-based recombinant PVM strain J3666 that incorporates the fluorescent tag monomeric Katushka 2 (mKATE2). The rK2-PVM pathogen promotes lethal infection in BALB/c mice and elicits characteristic cytokine production and leukocyte recruitment to the lung parenchyma. Using recombinant virus, we demonstrate for the first time PVM infection of both dendritic cells (DCs; CD11c(+) major histocompatibility complex class II(+)) and alveolar macrophages (AMs; CD11c(+) sialic acid-binding immunoglobulin-like lectin F(+)) in vivo and likewise detect mKATE2(+) DCs in mediastinal lymph nodes from infected mice. AMs support both active virus replication and production of infectious virions. Furthermore, we report that priming of the respiratory tract with immunobiotic Lactobacillus plantarum, a regimen that results in protection against the lethal inflammatory sequelae of acute respiratory virus infection, resulted in differential recruitment of neutrophils, DCs, and lymphocytes to the lungs in response to rK2-PVM and a reduction from ∼ 40% to <10% mKATE2(+) AMs in association with a 2-log drop in the release of infectious virions. In contrast, AMs from L. plantarum-primed mice challenged with virus ex vivo exhibited no differential susceptibility to rK2-PVM. Although the mechanisms underlying Lactobacillus-mediated viral suppression remain to be fully elucidated, this study provides insight into the cellular basis of this response.

IMPORTANCE

Pneumonia virus of mice (PVM) is a natural mouse pathogen that serves as a model for severe human respiratory syncytial virus disease. We have developed a fully functional recombinant PVM strain with a fluorescent reporter protein (rK2-PVM) that permits us to track infection of target cells in vivo. With rK2-PVM, we demonstrate infection of leukocytes in the lung, notably, dendritic cells and alveolar macrophages. Alveolar macrophages undergo productive infection and release infectious virions. We have shown previously that administration of immunobiotic Lactobacillus directly to the respiratory mucosa protects mice from the lethal sequelae of PVM infection in association with profound suppression of the virus-induced inflammatory response. We show here that Lactobacillus administration also limits infection of leukocytes in vivo and results in diminished release of infectious virions from alveolar macrophages. This is the first study to provide insight into the cellular basis of the antiviral impact of immunobiotic L. plantarum.

摘要

未标记

小鼠肺炎病毒(PVM)是一种天然的啮齿动物病原体,在支气管上皮细胞中复制,并再现了与人类呼吸道合胞病毒相关的更严重疾病形式的许多临床和病理特征。为了在体内急性感染期间追踪病毒与靶细胞的相互作用,我们开发了rK2-PVM,这是一种基于细菌人工染色体的重组PVM菌株J3666,它整合了荧光标签单体卡图什卡2(mKATE2)。rK2-PVM病原体在BALB/c小鼠中引发致死性感染,并引发特征性细胞因子产生以及白细胞向肺实质的募集。使用重组病毒,我们首次证明了树突状细胞(DCs;CD11c(+)主要组织相容性复合体II类(+))和肺泡巨噬细胞(AMs;CD11c(+)唾液酸结合免疫球蛋白样凝集素F(+))在体内均受到PVM感染,并且同样在感染小鼠的纵隔淋巴结中检测到mKATE2(+) DCs。AMs支持活跃的病毒复制和传染性病毒粒子的产生。此外,我们报告称,用免疫益生菌植物乳杆菌对呼吸道进行预处理(该方案可预防急性呼吸道病毒感染的致死性炎症后遗症),会导致在rK2-PVM刺激下,中性粒细胞、DCs和淋巴细胞向肺部的差异性募集,并且与传染性病毒粒子释放量下降2个对数级相关联,mKATE2(+) AMs从约40%减少至<10%。相比之下,在体外受到病毒攻击的植物乳杆菌预处理小鼠的AMs对rK2-PVM没有表现出差异性易感性。尽管植物乳杆菌介导的病毒抑制的潜在机制仍有待充分阐明,但本研究为这种反应的细胞基础提供了见解。

重要性

小鼠肺炎病毒(PVM)是一种天然的小鼠病原体,可以作为严重人类呼吸道合胞病毒疾病的模型。我们开发了一种带有荧光报告蛋白的功能完备的重组PVM菌株(rK2-PVM),它使我们能够在体内追踪靶细胞的感染情况。利用rK2-PVM,我们证明了肺部白细胞受到感染,特别是树突状细胞和肺泡巨噬细胞。肺泡巨噬细胞发生有效感染并释放传染性病毒粒子。我们之前已经表明,将免疫益生菌植物乳杆菌直接施用于呼吸道黏膜可保护小鼠免受PVM感染的致死性后遗症影响,同时可显著抑制病毒诱导的炎症反应。我们在此表明,施用植物乳杆菌还可在体内限制白细胞感染,并导致肺泡巨噬细胞释放的传染性病毒粒子减少。这是第一项深入了解免疫益生菌植物乳杆菌抗病毒作用细胞基础的研究。